Overview

Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria

Status:
Completed

Trial end date:
1998-07-01

Target enrollment:

Participant gender:

Summary

OBJECTIVES: I. Determine the efficacy of cysteine hydrochloride in preventing or decreasing photosensitivity in patients with erythropoietic protoporphyria.

Phase:

N/A

Details

Lead Sponsor:

FDA Office of Orphan Products Development

Collaborator:

St. Luke's-Roosevelt Hospital Center